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The Journal of Immunology
4-1BB Ligand Signaling to T Cells Limits T Cell Activation
So-Young Eun,* Seung-Woo Lee,† Yanfei Xu,* and Michael Croft*
4-1BB ligand (4-1BBL) and its receptor, 4-1BB, are both induced on T cells after activation, but little is known about the role of
4-1BBL. In this study we show that 4-1BBL can transmit signals that limit T cell effector activity under tolerogenic conditions.
Cross-linking 4-1BBL inhibited IL-2 production in vitro, primarily with suboptimal TCR stimulation. Furthermore, naive 4-1BBL–
deficient OT-II transgenic T cells displayed a greater conversion to effector T cells in vivo when responding to soluble OVA peptide
in wild-type hosts, whereas development of Foxp3+ regulatory T cells was not altered. A greater number of effector T cells also
differentiated from naive wild-type OT-II T cells when transferred into 4-1BB–deficient hosts, suggesting that APC-derived 4-1BB
is likely to trigger 4-1BBL. Indeed, effector T cells that could not express 4-1BBL accumulated in larger numbers in vitro when
stimulated with 4-1BB–expressing mesenteric lymph node dendritic cells. 4-1BBL was expressed on T cells when Ag presentation
was limiting, and 4-1BBL was aberrantly expressed at very high levels on T cells that could not express 4-1BB. Trans-ligation, Ab
capture, and endocytosis experiments additionally showed that T cell–intrinsic 4-1BB regulated internalization of membrane
4-1BBL, implying that the strong induction of 4-1BB on T cells may counteract the suppressive function of 4-1BBL by limiting its
availability. These data suggest that 4-1BBL expressed on T cells can restrain effector T cell development, creating a more
favorable regulatory T cell to effector cell balance under tolerogenic conditions, and this may be particularly active in mucosal
barrier tissues where 4-1BB–expressing regulatory dendritic cells present Ag. The Journal of Immunology, 2015, 194: 134–141.
T
umor necrosis factor and TNFR superfamily interactions
play crucial roles in regulating proinflammatory as well as
anti-inflammatory responses in autoimmune diseases (1,
2). Among these, the binding of 4-1BB to 4-1BB ligand (4-1BBL)
has been documented to promote cell activation, survival, and
differentiation, primarily through 4-1BB signaling activity in
T cells, NK cells, and dendritic cells (DCs). However, there have
been reports that 4-1BB–deficient T cells and myeloid lineage
cells hyperproliferate (3, 4), suggesting that the interaction be-
tween 4-1BB and 4-1BBL might also be suppressive in certain
situations. This suppressive action may be transmitted through
4-1BB itself, leading to production of modulatory molecules such
as retinaldehyde dehydrogenase (RALDH) in DCs as recently
described (5). However, such suppressive function may also be
attributed in alternate scenarios to signals emanating from
4-1BBL. Although 4-1BBL was originally thought to be simply
a ligand for 4-1BB (6), there has been accumulating evidence that
it can transduce signals when interacting with 4-1BB (7, 8). Cross-
linking 4-1BBL was shown to promote or suppress immune cell
differentiation, suggesting that the result of 4-1BBL signaling is
likely to be cell-specific and/or context-dependent (4, 9–11). In
particular, ligation of 4-1BBL with an Fc fusion protein of 4-1BB
promoted IL-10 production in bone marrow–derived macrophages,
supporting its potential suppressive functionality (10), and several
studies with 4-1BB–Fc or 4-1BB–expressing cells have reported
inhibition of T cell responsiveness, implying a negative activity of
4-1BBL (3, 12, 13). Despite some reports finding evidence of ex-
pression of 4-1BBL on activated T cells (6, 14), 4-1BBL is usually
barely detectable, and thus the regulation and primary function of
4-1BBL on this cell type is still not clear.
In this study, we demonstrate a T cell–intrinsic regulation of
4-1BBL by 4-1BB itself when 4-1BB is strongly induced in
a T cell. We find that 4-1BBL signaling can play a very early rate-
limiting step in Ag-dependent T cell activation, under conditions
of limiting Ag presentation and inflammation, when 4-1BB is not
highly expressed, suppressing IL-2 production and effector T cell
clonal expansion. We also show that the physiological relevance
of 4-1BBL–mediated suppressive function in T cells may manifest
in microenvironments such as the GALT where 4-1BB–expressing
DCs may encounter recently activated T cells that express 4-1BBL,
further adding to the ability of regulatory APCs to limit the dif-
ferentiation or expansion of effector T cells.
Materials and Methods
Mice
Eight- to 10-wk-old C57BL/6 (B6) mice or Ly5.1 congenic B6 mice were
purchased from The Jackson Laboratory. 4-1BB2/2 or 4-1BBL2/2 OT-II
TCR transgenic mice were generated by crossing OT-II mice with 4-1BB2/2
mice (from B.S. Kwon) (3) or 4-1BBL2/2mice (from Amgen), respectively,
and maintained at La Jolla Institute for Allergy and Immunology. All
experiments were done in compliance with the regulations of the La Jolla
Institute for Allergy and Immunology Animal Care Committee in accor-
dance with guidelines of the Association for the Assessment and Ac-
creditation of Laboratory Animal Care.
Murine 4-1BB and 4-1BBL constructs
Murine 4-1BB cDNA was synthesized by RT-PCR using total RNA from
activated splenic CD4 T cells of B6 mice. Full-length (256 aa) and cyto-
plasmic tail-deleted (DC, 213 aa) 4-1BB expression constructs were gen-
erated in pBABE-puro backbone (a gift of Dr. Chris Benedict, La Jolla
Institute for Allergy and Immunology) tagged with myc (59-GAGCA-
GAAGCTGATCAGCGAGGAAGACCTG-39, EQKLISEEDL) in the N
terminus and His6 (59-CACCATCACCATCACCAT-39, HHHHHH) in the
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C terminus. Murine 4-1BBL cDNA was obtained from total RNA of splenic
CD11c+ cells by RT-PCR. 4-1BBL (full length of 309 aa) was also inserted
into pBABE-puro with an N-terminal FLAG tag (59-GACTACAAGGACG-
ATGACGATAAG-39, MDYKDDDDK) and a C-terminal hemagglutinin tag
(59-TACCCTTATGACGTGCCAGATTACGCC-39, YPYDVPDYA).
Cells and in vitro cultures
CD4+ T cells were enriched from the spleen and lymph nodes of wild-type
(WT), 4-1BB2/2, or 4-1BBL2/2 mice on the OT-II TCR transgenic
background by using a CD4 T cell isolation kit with LS columns (Miltenyi
Biotec), according to the manufacturer’s instructions. Naive (CD44lo
CD62LhiCD252) CD4+ T cells were further purified by FACS. T cells (23
105/200 ml) were cultured either with DCs (1–4 3 104) and various
amounts of OVA323–339 peptide Ag or with variable concentrations of
immobilized anti-CD3 (2C11) and 2.5 mg/ml soluble anti-CD28 (37N5) in
each well of 96-well plates at 37˚C with 5% CO2. In some experiments, rat
anti-mouse 4-1BB (3H3, originally from Dr. Robert Mittler, Emory Uni-
versity), rat anti-mouse 4-1BBL (19H3, also from Dr. Robert Mittler), or
4-1BB–Fc (15) were added to the culture in soluble or immobilized forms
(20 mg/ml). Rat IgG (Sigma-Aldrich) and human IgG1 Fc (Millipore) were
used as controls and added soluble or immobilized in the exact manner as
the 4-1BB/4-1BBL reagents. For endocytosis inhibition assays, chlor-
promazine or genistein (Sigma-Aldrich) was added to the culture for the
final 6 h. For regulatory T (Treg) cell conversion experiments, 4-1BB–
expressing CD11c+MHC class IIhi DCs from mesenteric lymph nodes
(MLNs) were pre-enriched by removing T/B lymphocytes, NK cells,
and gdT cells using biotinylated anti-CD3ε, anti-B220, anti-DX5a, and
anti-gdTCR (eBioscience) along with the EasySep Mouse Streptavidin
RapidSpheres Isolation Kit (StemCell Technologies) according to the
manufacturers’ instructions, and then further sorted by FACS using FITC-
conjugated anti-CD11c, Pacific Blue–conjugated anti–I-A/I-E (BioLegend),
biotinylated anti–4-1BB with allophycocyanin-conjugated streptavidin
(eBioscience). Recombinant human TGF-b1 (R&D Systems) was used for
Treg cell conversion assays. In some cases, purified naive CD4 T cells were
labeled with 0.5 mM CFSE (Invitrogen).
T hybridoma cells were generated from activated 4-1BB2/2 OT-II
T cells fused with the BW5147 thymoma, and selected based on produc-
tion of IL-2. Myc-tagged full-length or cytoplasmic region–deleted 4-1BB
vectors were packaged in HEK293T cells, and supernatants were used to
introduce the constructs into the T hybridoma cells by centrifugation at
3000 rpm for 2 h at room temperature. 4-1BB–expressing hybridoma cells
were selected with 0.75 mM puromycin treatment and purified by FACS
based on Myc tag expression. In experiments, 1 3 105 cells were cocul-
tured with mock-transfected T hybridoma cells (1 3 105) in 200 ml
volumes for 24 h. To stimulate 4-1BBL via cell-to-cell interaction,
recombinant 4-1BB was introduced into 3T3 fibroblasts or thymoma cells
by retroviral transduction as described above, and used as 4-1BB–expressing
accessory cells along with 4-1BB2 mock cells as controls.
Adoptive transfer, Ag administration, and ex vivo analysis
Purified naive WT or 4-1BBL2/2 OT-II T cells (2 3 106) were i.v.
transferred into congenic Ly5.1 B6 mice. In some experiments, WT and
4-1BB2/2 B6 mice were used as recipients of WT Ly5.1+ congenic OT-II
T cells. Twenty-four hours after transfer, 5 mg OVA323–339 peptide was
injected in PBS into each mouse through the tail vein. At day 3, 6, or 9
after peptide administration, spleens and lymph nodes were analyzed by
flow cytometry for accumulation of OT-II T cells (Va2+Vb5+Ly5.2+) with
an effector phenotype (CD44hiCD62Llo) or Treg phenotype (Foxp3+).
Splenocytes, harvested at day 3, were also restimulated with PMA (5 ng/ml)
and ionomycin (500 ng/ml), and culture supernatants were assayed for
production of IL-2 and IFN-g by ELISA. In an alternate protocol, soluble
OVA peptide was injected 24 h after adoptive transfer (25 mg) and then again
4 d later (10 mg). Transferred OT-II T cells from spleens and lymph nodes
were then analyzed 3 d after the second challenge (day 7) by flow cytometry.
Flow cytometry
For 4-1BB and 4-1BBL detection, biotinylated anti–4-1BB (17B5) and
anti–4-1BBL (TKS-1) Abs were used, respectively, along with biotinylated
rat IgG2a as an isotype control, plus streptavidin-conjugated allophyco-
cyanin (all from eBioscience). For analyzing activated T cells, anti–CD44-
FITC, anti–CD62L-allophycocyanin, anti–Va2-Pacific Blue, anti–Vb5-PE,
and anti–CD4-allophycocyanin-Cy7 were used, along with anti-CD45.1 or
anti–CD45.2-PerCP-Cy5.5. For detection of Foxp3+ Treg cells, anti–
Foxp3-PerCP-Cy5.5 was used along with other T cell markers including
anti–CD25-PE-Cy7 (all from eBioscience).
ELISA
Unlabeled anti-mouse IL-2 (0.5 mg/ml) or anti-mouse IFN-g (0.5 mg/ml),
biotinylated anti-mouse IL-2 or IFN-g, and streptavidin-conjugated HRP
(BD Biosciences) were used in conventional ELISA assays to assess IL-2
or IFN-g secretion using tetramethylbenzidine substrate reagents (Bio-
Legend). The OD was read at 450 nm on a SpectraMax 250 (Molecular
Devices). The amount of IL-2 or IFN-g in each sample was determined
based on the standard curve generated with serially diluted recombinant
murine IL-2 or IFN-g (PeproTech).
Immunofluorescence microscopy
Activated T cells (2 3 105) were loaded onto each poly-L-lysine–coated
coverslip (BD Biosciences), fixed with 4% paraformaldehyde/PBS for 15
min, permeabilized with 0.3% saponin/PBS for 5 min, treated with
5% BSA/PBS for 30 min, and stained with anti–4-1BBL goat pAb (R&D
Systems) and biotinylated anti–4-1BB (3E1) mAb (biotinylated using 3E1
Ab, a gift from Dr. Robert Mittler, Emory University) for 1 h, followed by
donkey anti-goat IgG (H+L)–Alexa Fluor 488 and streptavidin–Alexa
Fluor 647 (Invitrogen) for another hour. Cells were washed with PBS three
times between the steps. Cellular nuclei were revealed with DAPI staining.
Immunofluorescent images were obtained under Zeiss Axiovert 200M
microscope integrated with Intelligent Imaging Innovations slidebook 4.2
and analyzed using ImageJ software.
Statistical analysis
All statistical analyses were performed using a two-tailed Student t test.
Results
4-1BBL is induced on activated T cells but downregulated
when 4-1BB is strongly expressed
Certain TNF family ligands have been characterized as primarily
expressed on T cells, notably molecules such as CD40L and
LIGHT. However, it is not clear whether ligands for many of the
TNF family receptors that are costimulatory for T cells, such as
4-1BB, OX40, GITR, and CD27, are also ubiquitously present, and
what might regulate their availability. Understanding this is also
complicated by the fact that many TNF family ligands might be
cleaved from the cell membrane or regulated by endocytosis.
4-1BBL is normally hard to detect on T lymphocytes, but we found
that 4-1BB–deficient T cells displayed high levels of 4-1BBL on
their surface upon activation (Fig. 1A). This type of regulation is
consistent with previous studies that revealed higher levels of
4-1BBL on hematopoietic stem cells and DC precursors when
obtained from 4-1BB–deficient animals (4). Suggesting this was
not related to abnormal activity of 4-1BB–deficient T cells, we
also found that an anti–4-1BBL Ab that can block the interaction
of 4-1BB with 4-1BBL also revealed strong expression of surface
4-1BBL by flow cytometry and in confocal experiments when
added in soluble form into WT T cell cultures (Fig. 1B, 1C). Anti–
4-1BBL may have simply captured 4-1BBL on the cell surface;
however, Abs directed to 4-1BB also revealed surface 4-1BBL
(data not shown), suggesting that an interaction between the two
molecules reduces the amount of 4-1BBL present on the T cell
surface. We also found that intracellular levels of 4-1BBL were
higher in 4-1BB2/2 than in WT T cells, as well as in WT T cells
cultured in the presence of anti–4-1BBL (Fig. 1D). 4-1BBL be-
came detectable on the cell surface after 15 min at low levels and
was highly expressed between 24 and 48 h upon addition of sol-
uble anti–4-1BBL, correlating with the normal induction kinetics
of the receptor (data not shown and Fig. 1). This suggests that
4-1BBL is produced and potentially available to play a functional
role after T cells are activated, but when 4-1BB is made at high
levels, it can limit the expression of its own ligand.
To further study this, a T cell hybridoma was generated from
4-1BB–deficient primary activated T cells and then retrovirally
transduced with 4-1BB. Parent T hybridoma cells endogenously
expressed surface 4-1BBL due to the lack of 4-1BB, and trans-
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duction with mock vector did not alter this endogenous expres-
sion (Fig. 2A). In contrast, transduction with full-length 4-1BB
resulted in strongly diminished the levels of surface 4-1BBL.
Introduction of a cytoplasmic domain–deleted mutant form of
4-1BB (DC 4-1BB) also reduced surface 4-1BBL to a similar
degree. This showed that the cytoplasmic tail of 4-1BB and
signaling through 4-1BB are dispensable for this activity, and
again suggested that the reduction of expression of 4-1BBL
requires an interaction with 4-1BB. To then determine whether
4-1BB could suppress surface 4-1BBL expressed on a neigh-
boring cell (in trans), mock-transduced cells expressing endog-
enous 4-1BBL were cocultured at 1:1 ratio for 24 h with cells
transduced with full-length or DC 4-1BB. 4-1BB expressed in
trans did not alter the level of 4-1BBL expressed on the mock
cells (Fig. 2B), indicating that T cell–intrinsic expression of
4-1BB limits 4-1BBL levels in the same cell through a cis in-
teraction, either intracellularly or on the membrane.
We then performed assays to block endocytosis to determine
whether this is one of the mechanisms by which 4-1BBL ex-
pression is controlled on the T cell surface (Fig. 3). A 6-h
treatment of WT T cells with genistein, an inhibitor of caveolin-
mediated endocytosis, resulted in expression of surface 4-1BBL
at similar levels to those detectable on 4-1BB–deficient T cells.
In contrast, an inhibitor of clathrin-mediated endocytosis,
chlorpromazin, had little effect on the expression of 4-1BBL.
Quantitative PCR analysis from activated WT and 4-1BB2/2
T cells showed no difference in expression of mRNA for 4-1BBL
(data not shown), suggesting that the dominant mechanism for
4-1BB–facilitated downregulation of 4-1BBL is posttranscrip-
tional. Because intracellular levels of 4-1BBL were also decreased
in WT T cells compared with 4-1BB–deficient T cells, or in WT
T cells treated with anti–4-1BBL blocking Ab (Fig. 1D), these
data then suggest that 4-1BBL protein is degraded after endocy-
tosis triggered by 4-1BB.
4-1BBL signaling limits T cell activation in vitro
As there was a reciprocal relationship between expression of
4-1BBL and its receptor, this implied that 4-1BBL might be
functionally active in activated T cells in certain situations where
4-1BB might not be optimally induced. Thus, we first tested whether
signaling through 4-1BBL, brought about by cross-linking with
immobilized anti–4-1BBL or an Fc fusion of 4-1BB, would have
any effect on the response of T cells to TCR stimulation with or
without costimulation through CD28. Significantly, T cell acti-
vation to varying doses of anti-CD3 with anti-CD28 was sup-
pressed in the presence of immobilized anti–4-1BBL, as determined
by assessing the levels of secreted IL-2 (Fig. 4A). Notably, this
FIGURE 1. Expression of 4-1BB and 4-1BBL on
activated T cells. WT, 4-1BB2/2, and 4-1BBL2/2
naive OT-II CD4 T cells were either activated with
WT DCs and 1 mM OVA peptide for varying lengths
of time (A) or anti-CD3 and anti-CD28 in the pres-
ence of soluble anti–4-1BBL (19H3) or control IgG
for 48 h (B–D). (A and B) 4-1BB and 4-1BBL surface
expression in gated CD44hiVa2+Vb5+ T cells by
flow cytometry. (C) 4-1BB and 4-1BBL expression in
T cells from (B) analyzed by confocal microscopy.
Green, 4-1BBL; red, 4-1BB. Original magnification
380. (D) Intracellular staining for 4-1BBL (top) after
surface 4-1BBL was stained with saturating amounts
of the same detection Ab conjugated to a different
dye. Data are representative of three to five indepen-
dent experiments.
FIGURE 2. T cell–intrinsic suppression of 4-1BBL expression by
4-1BB. (A) 4-1BB–deficient CD4 T hybridoma cells mock transfected or
transfected with Myc-tagged full length (FL) 4-1BB or C term–deleted
mutant (DC) 4-1BB were stained for membrane 4-1BB and 4-1BBL.
(B) FL 4-1BB– or DC 4-1BB–transfected T hybridoma cells (1 3 105)
were cocultured at a 1:1 ratio with mock-transfected T hybridoma cells
(expressing endogenous 4-1BBL) for 24 h and stained for membrane 4-1BB
and 4-1BBL. All data are representative of two independent experiments.
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activity of binding 4-1BBL was strongest under conditions of
suboptimal stimulation with anti-CD3. Varying the dose of anti-
CD28 did not alter the suppressive effect (not shown). CFSE dilu-
tion assays also showed a significant decrease in the number of cell
divisions as well as the total number of dividing cells in the pres-
ence of immobilized anti–4-1BBL, with this effect limited to low
doses of anti-CD3, correlating with the action on IL-2 production
(Fig. 4B and data not shown). To verify that suppression of T cell
activation was a direct result of signaling through 4-1BBL and
not because of disrupting 4-1BB/4-1BBL interactions, 4-1BB2/2
T cells that express higher levels of endogenous 4-1BBL were also
tested. Immobilized anti–4-1BBL suppressed IL-2 production to
a similar extent in 4-1BB2/2 T cells compared with WT T cells
(Fig. 4A). An equivalent effect was also seen with immobilized
4-1BB–Fc (Fig. 4C) showing suppression was not Ab specific but
could result when 4-1BBL bound its natural partner. Similarly,
4-1BBL–expressing T hybridoma cells derived from activated
4-1BB2/2 OT-II cells also produced lower levels of IL-2 when
stimulated with anti-CD3 or anti-CD3/anti-CD28 in the presence
of immobilized 4-1BB–Fc (Fig. 4D). The suppressive activity was
further confirmed by using irradiated accessory cells that expressed
4-1BB to ligate 4-1BBL on these T cells. Reduced IL-2 production
was observed compared with T cells cultured with accessory cells
that lacked 4-1BB (Fig. 4E). These data collectively suggest that
4-1BBL plays a suppressive role in T cell activation under con-
ditions of suboptimal stimulation. This negative activity is con-
trolled when T cells are stimulated strongly to express high levels of
4-1BB, which in cis configuration facilitates the removal of 4-1BBL
from the T cell surface by endocytosis.
FIGURE 3. 4-1BBL surface expression is regulated by endocytosis. WT
naive CD4 T cells were activated with anti-CD3 and anti-CD28. After
42 h, endocytosis blockers, chlorpromazine (CPZ; 10 mg/ml) or genistein
(500 mM), were added to the cultures and incubated for an additional 6 h.
Controls were nontreated (NT) or DMSO treated. Cells were stained for
membrane 4-1BBL. 4-1BB2/2 T cells were also cultured as an additional
positive control for 4-1BBL expression. (A) Flow plots. (B) Mean fluo-
rescence intensity (MFI) of 4-1BBL among the different groups. Data are
representative of two independent experiments.
FIGURE 4. T cell activation is suppressed by
4-1BBL signaling. (A) WT and 4-1BB2/2 naive CD4
T cells were stimulated with various concentrations of
anti-CD3 and 2.5 mg/ml anti-CD28 in the presence of
plate-bound anti–4-1BBL (20 mg/ml) or control IgG.
IL-2 was assessed at 48 h by ELISA. Right panel
shows data magnified from left panel (gray boxes). (B)
CFSE-labeled naive CD4 T cells were stimulated with
0.1 mg/ml anti-CD3 and 2.5 mg/ml anti-CD28 in the
presence of plate-bound anti–4-1BBL or control IgG for
48 h. CFSE dilution was assessed (left) and CD4 T cell
recovery was calculated (right). (C) Naive 4-1BB2/2
CD4 T cells were stimulated with a low dose of plate-
bound anti-CD3 and anti-CD28 as in (A) in the presence
of plate-bound anti–4-1BBL or 4-1BB–Fc (20mg/ml), or
control rat IgG or human IgG1 Fc. IL-2 was assessed at
48 h by ELISA. (D) 4-1BB2/2 T hybridoma cells were
activated with anti-CD3 (0.1 mg/ml) with or without
anti-CD28 (2.5 mg/ml) in the presence of plate-bound
4-1BB–Fc or control human IgG1 Fc (20 mg/ml). IL-2
was assessed at 6 h by ELISA. (E) 4-1BB2/2 T hy-
bridoma cells were activated with various concentrations
of anti-CD3 in the presence of irradiated accessory cells
(AC) that did or did not express 4-1BB. IL-2 was
assessed at 6 h by ELISA. Data are representative of five
independent experiments and are means 6 SEM from
replicate cultures.
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4-1BBL signaling limits effector T cell development in vivo
under noninflammatory conditions
To investigate any physiological relevance of these results, we
assessed conditions in vivo where peptide was recognized under
noninflammatory/tolerogenic conditions that favor development of
Foxp3+ Treg cells and that might mimic the scenario we found
in vitro where 4-1BBL was actively suppressive in T cells (16). The
response of naive TCR transgenic T cells that could or could not
express 4-1BBL was tracked when adoptively transferred into WT
hosts. With systemic injection of a low dose of OVA peptide Ag in
PBS, we found that the absence of 4-1BBL2/2 on the responding
naive T cells resulted in accumulation of ∼3-fold more effector
T cells (CD44hi, CD62lo) in spleens or lymph nodes when assessed
after 3 d (Fig. 5A, left). In contrast, a similar number of Foxp3+
OT-II Treg cells developed regardless of the presence or absence
of 4-1BBL on the responding T cells (Fig. 5A, middle). The en-
hanced numbers of effector T cells generated in the absence of
4-1BBL was maintained at day 6, although the absolute numbers
were reduced compared with day 3 regardless of being WT or
4-1BBL2/2 (Fig. 5A, left). After 9 d, we could not detect effector
T cells regardless of being WT or 4-1BBL2/2 (not shown).
Consistent with this being a tolerogenic response, Foxp3+ Treg
cells were maintained over this time period and were similar in
number in both groups (not shown). These data suggested that
4-1BBL principally acted to limit the generation of effector T cells
as Treg cells were forming to aid in the development of tolerance.
In line with this, higher levels of IL-2 and IFN-g were detected in
splenic cultures from mice receiving 4-1BBL2/2 T cells (Fig. 5B).
To ascertain whether the suppressive activity of 4-1BBL on T cells
came from its interaction with 4-1BB expressed in the hosts,
presumably on APCs, 4-1BB2/2 mice were used as recipients of
WT OT-II T cells. Two- to 3-fold higher numbers of OVA-specific
T cells of the effector phenotype were generated in 4-1BB2/2
recipients, paralleling the observation with 4-1BBL–deficient
T cells (Fig. 5C). In contrast, there was no significant difference in
the numbers of Foxp3+ Treg cells generated in both groups.
To test the effect of 4-1BBL in another system, we challenged
mice twice with soluble OVA peptide in PBS, with the second
injection given after 4 d, and then assessed the number of effector
T cells generated after a further 3 d (7 d total). In this scenario,
higher numbers of effector T cells were maintained over this time
frame compared with a single peptide injection, but importantly the
difference between WT and 4-1BBL2/2 T cells was maintained at
an ∼1:3 ratio (Fig. 5D). Again, Foxp3+ Treg cells were generated
FIGURE 5. 4-1BBL limits T cell activation
in vivo under noninflammatory conditions. (A)
Sorted naive WT or 4-1BBL2/2 (L2/2) Ly5.2+
OT-II T cells (2 3 106) were adoptively
transferred into WT Ly5.1+ congenic recipient
mice. One day later, mice were immunized i.v.
with 5 mg OVA323–339 peptide in PBS. After 3 d
(left and middle) or 6 d (right), the number
of effector (CD44hiCD62Llo) or Foxp3+ OT-II
(Va2+Vb5+Ly5.2+) T cells was calculated in
spleens (SPL) and peripheral lymph nodes
(pLNs). (B) Splenocytes from (A), taken at day
3, were stimulated with PMA (5 ng/ml) and
ionomycin (500 ng/ml) for 5 h, and IL-2 and
IFN-g production were measured by ELISA.
(C) Sorted naive Ly5.1+ congenic WT OT-II
T cells were transferred into WT or 4-1BB2/2
(R2/2) Ly5.2+ recipients. Mice were immu-
nized and analyzed at day 3 as in (A). (D)
Recipients of 4-1BBL2/2 T cells were chal-
lenged with 25 mg OVA peptide in PBS similar
to (A) and then rechallenged with 10 mg OVA
peptide 4 d later. Accumulation of effector and
Foxp3+ OT-II T cells was analyzed after a fur-
ther 3 d. All data show numbers of T cells or
amounts of each cytokine in individual recipi-
ent mice, with means 6 SEM for each group,
and are representative of at least two indepen-
dent experiments in each case. *p , 0.05,
**p , 0.01, ***p , 0.001.
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equally regardless of the absence of 4-1BBL. Furthermore, we
observed no significant difference in the response of 4-1BBL–
deficient T cells compared with WT T cells when the adjuvant
aluminum hydroxide was given along with OVA peptide using
a similar immunization protocol that does not generate significant
numbers of Treg cells (data not shown). Thus, 4-1BBL expressed
on T cells suppresses the initial accumulation and differentiation
of effector populations under noninflammatory conditions where
Treg cells are also generated, but it has no apparent role in the
T cell response under inflammatory conditions.
4-1BB–4-1BBL interactions between regulatory DCs and
T cells limits T cell activation
Previously we reported that a proportion of MLN DCs implicated
in promoting the generation of Foxp3+ Treg cells constitutively
expressed 4-1BB. This is the subset that also expresses CD103 and
makes high levels of the regulatory enzyme RALDH that controls
retinoic acid production. We furthermore found that 4-1BB par-
ticipated in the development of this subset of regulatory DCs from
precursors by determining the level of expression of RALDH (5).
To assess whether 4-1BB on these DCs may also promote sup-
pressive activity by binding T cell–expressed 4-1BBL, WT or
4-1BBL2/2 naive OT-II T cells were cocultured with sorted
4-1BB–expressing MLN DCs (CD11c+MHC class IIhi4-1BB+).
4-1BBL2/2 effector T cells accumulated to a greater extent with
a low dose of Ag (Fig. 6A), in line with limiting Ag or inflammation
revealing the suppressive effect of 4-1BBL. With a high dose of
Ag, 4-1BB was strongly induced on WT T cells whereas its expres-
sion was weaker with a low dose of Ag (Fig. 6B). Correspondingly,
4-1BBL was readily detectable with a low dose of Ag, expressed
together with 4-1BB, but it was much more weakly detectable
with a high dose of Ag when 4-1BB was present at higher levels
(Fig. 6B). This likely accounts for why it was functionally relevant
under the former conditions.
Despite that 4-1BBL signaling did not alter Foxp3+ Treg cell
differentiation in the conditions of immunization we used in vivo
(Fig. 5), it remained possible that 4-1BBL signaling might con-
tribute to the proportion of Treg cells that are generated in certain
microenvironments such as the GALT where TGF-b is strongly
expressed and 4-1BB–expressing DCs are found. To test this
in vitro, sorted 4-1BB+ MLN DCs were cultured with 4-1BBL2/2
T cells in the presence of TGF-b. A significantly reduced per-
centage of Foxp3+ Treg cells were generated when 4-1BBL could
not be expressed (3.3 versus 9.6%). This was limited to the cul-
tures with a low dose of Ag whereas with a high dose of Ag no
defect in Treg cell generation was apparent (Fig. 6C). This again
correlated with little detectable 4-1BBL and strong 4-1BB ex-
pression under the latter conditions, whereas we again observed
with a low dose of Ag that 4-1BBL was more strongly expressed
and most of the 4-1BBL–expressing cells also coexpressed 4-1BB
(Fig. 6C and data not shown). In the cultures with limiting Ag,
there were also many T cells that neither expressed 4-1BB or
4-1BBL, most likely because they were not stimulated well
through the TCR. Thus, 4-1BBL can exert suppressive activity in
T cells to limit effector cell development under conditions of weak
Ag presentation or no inflammation, and in certain conditions
4-1BBL may also participate in allowing greater development of
Treg cells by ligating 4-1BB on APCs.
Discussion
A growing number of autoinflammatory and allergic disorders
have been identified in humans, most of which are attributed to
hyperresponsiveness of T lymphocytes against potentially harmless
foreign or self-antigens. T cells have multiple ways to limit their
responsiveness to nonpathogenic stimuli. In the present study, we
demonstrate that ligation of 4-1BBL on T cells can function in this
regard and suppress T cell activation and early expansion of ef-
fector T cells. 4-1BBL was induced upon Ag-dependent activation
of T cells under tolerizing conditions in vitro as well as in vivo and
was active in this inhibitory capacity when inflammation and Ag
presentation were suboptimal.
Although much of the literature on the interaction of 4-1BB and
4-1BBL has focused on the stimulatory capacity of 4-1BB on
various cell types, including T cells, there is a growing body of
research showing that 4-1BBL itself can signal. However, whether
this provides a stimulatory or inhibitory stimulus appears to vary
and may be both cell type specific and context-dependent. 4-1BBL
signaling has been illustrated in myeloid cells as well as
in lymphocytes. Cross-linking of 4-1BBL with immobilized
4-1BB–Fc, anti–4-1BBL mAb, or 4-1BB–expressing cells can
lead to monocyte and DC activation, proliferation, maturation,
production of proinflammatory cytokines such as IL-6, IL-8, TNF,
or IL-12, and/or cell survival (11, 17–22). However, there is ac-
cumulating evidence of negative regulatory roles for 4-1BBL
signaling in activation and/or differentiation of varying types of
cells, including bone marrow myeloid precursors, osteoclasts, as
FIGURE 6. 4-1BBL signaling in T cells limits T cell activation and
favors Treg cell generation with low-dose Ag. (A) Naive WT or 4-1BBL2/2
OT-II T cells were cultured with sorted 4-1BB+ MLN DCs (MHC class IIhi,
CD11c+) at 20:1 ratios with 0.02 or 1 mMOVA peptide for 72 h. Recovery of
effector phenotype OT-II T cells (CD44hiCD62Llo) was determined. Data are
means 6 SEM from triplicate cultures. (B) T cells from cultures in (A) were
analyzed for expression of 4-1BBL and 4-1BB by flow cytometry (left) and
confocal microscopy (right). Original magnification 380. Green, 4-1BBL;
red, 4-1BB. (C) T cells were cultured as in (A) but in the presence of 5 ng/ml
TGF-b1. Percentages of Foxp3+ OT-II T cells were determined with cos-
taining for CD25 after 5 d (left), and expression of 4-1BBL and 4-1BB on
total OT-II T cells was assessed after 3 d (right). All data are representative
of three independent experiments. *p , 0.05.
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well as T cells (3, 4, 9, 10, 12, 23, 24). In particular, Schwarz et al.
(12) first suggested the potential regulatory activity of 4-1BBL
signaling by showing suppressed proliferation of human PBMC
T cells when cocultured with fixed 4-1BB–expressing cells. The
inhibitory activity of 4-1BBL signaling was not restricted to hu-
man PBMCs, but was also replicated in mouse splenocytes stim-
ulated with anti-CD3 where the proliferation of 4-1BB–deficient
T cells was reduced again when these cells were incubated with
4-1BB–expressing cells (3, 25).
We now add to these studies and suggest the suppressive activity
of 4-1BBL on T cells is regulated by its own receptor. 4-1BB has
long been known as an inducible molecule on T cells that transmits
costimulatory signals to augment division, survival, and cytokine
production under inflammatory conditions. We found that when
4-1BB was strongly induced, this resulted in the downregulation of
4-1BBL via a cis interaction that may largely occur on the T cell
surface but might also be functional intracellularly. This was most
dramatically illustrated with T cells that could not express 4-1BB
where 4-1BBL was readily and easily detected at high levels on
the cell surface. The plausible mechanisms limiting expression of
4-1BBL included shedding or cleavage from the membrane as
well as internalization. We do not favor the former because al-
though we could detect soluble 4-1BBL in the supernatant of ac-
tivated T cells, we found as much, and in some cases more, soluble
4-1BBL in cultures of 4-1BB2/2 T cells (data not shown). This is
opposite to what would be predicted if a cis interaction with 4-1BB
enhanced shedding or cleavage. In contrast, our data with confocal
analyses and using endocytosis inhibitors support the idea that
4-1BB binding to 4-1BBL results in its internalization and subsequent
degradation. This appears to be a mechanism by which the strong
induction of 4-1BB maximizes its potential to be a costimulatory
molecule for the T cell when 4-1BBL is upregulated on APCs under
inflammatory conditions, reducing any potential negative effect of its
ligand when a T cell encounters an APC that expresses 4-1BB.
The physiological significance of the immunoregulatory role of
4-1BBL engagement on T cells will be primarily evident in non-
inflammatory states or tolerizing conditions based on our data in vitro
and in vivo. The mechanism we describe depends on a source of
4-1BB in trans, and this is most likely provided by APCs that can
express 4-1BB. These are largely predicted to be DCs. Given the
inhibitory activity of 4-1BBL, it would make sense that 4-1BB
was provided on a tolerogenic or regulatory DC. The most obvious
example of this cell is the CD103+ DCs found in the MLNs, which
we previously described expressed 4-1BB directly ex vivo (5). In
line with this, we showed that expression of 4-1BB on a subpopu-
lation of MLN DCs coincided with those cells that had the greatest
ability to make retinoic acid. Indeed, ligation of 4-1BB sustained
the activity of the enzyme RALDH, which promotes retinoic acid
production in these MLN DCs. 4-1BB signaling additionally pro-
moted RALDH activity in splenic DCs when they upregulated
4-1BB after stimulation with TLR2 ligand or GM-CSF. This in turn
led to a greater ability of the DCs to promote the generation of
Foxp3+ Treg cells (5). Therefore, by blocking T cell activation
through 4-1BBL, as well as upregulating retinoic acid production
through 4-1BB signaling to the DCs, there can be synergistic sup-
pression of the T cell response. As we show in vitro, this may in
some cases also aid the generation of Foxp3+ Treg cells. Such bi-
directional signaling activity is likely to occur in mucosal tissues
such as the gastrointestinal tract where TGF-b is available along
with constant or periodic low-level stimulation of T cells by in-
nocuous Ags from food or commensals. This hypothesis is further
supported by our unpublished data, which show reduced numbers of
Foxp3+ Treg cells in the Peyer’s patches and small intestinal lamina
propria of 4-1BB2/2 and 4-1BBL2/2 mice.
In summary, we show a rate-limiting activity of 4-1BBL when
expressed by recently activated T cells that suppresses T cell acti-
vation and effector cell development under tolerizing conditions or
conditions where Ag presentation occurs at a low level with little
inflammation. The data highlight the complex interplay between
ligands and receptors in the TNF/TNFR superfamily. How intra-
cellular signals from 4-1BBL exert a suppressive effect in T cells is
not known, but understanding this will be important for future studies.
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